Concepedia

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Martha Q. Lacy, Suzanne R. Hayman, Morie A. Gertz, Kristen Detweiler Short, Angela Dispenzieri, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J. Russell, David Dingli,

Leukemia · 2010 · 198 citations · 14 references

DOIFull text

Open access

Concepts

References

14

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations

, , +12

Thalidomide is an inhibitor of angiogenesis.

Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations

, , +14

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies, Noopur Raje, Teru Hideshima et al. · Blood · 2001 · 905 citations

, , +12

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

Laura G. Corral, Patrick Haslett, George W. Muller et al. · PubMed · 1999 · 731 citations

, , +17

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Nicholas Mitsiades, Constantine S. Mitsiades, Vassiliki Poulaki et al. · Blood · 2002 · 667 citations · Full text

, , +17